Pharmaceutical News

Lilly Challenges Medicare's Exclusion of Obesity Drugs Eli Lilly Zepbound Eli Lilly challenges CMS's 2026 Medicare Part D ruling that excludes coverage for obesity drugs like Zepbound and Wegovy, citing risks to patient care and provider autonomy amid rising concerns over healthcare access and costs.
Sanofi Acquires Vigil Neuroscience for $470M Sanofi Alzheimers Sanofi acquires Vigil Neuroscience for $470M upfront, aiming to advance Alzheimer’s research with TREM2-targeting drug VG-3927. The deal may reach $600M with milestones and strengthens Sanofi’s neurology pipeline.
Sanofi Acquires Oral Alzheimer’s Drug VG-3927 for $470M Sanofi Biotech Sanofi acquires Vigil Neuroscience for $470M to gain rights to VG-3927, a promising once-daily oral TREM2 agonist for Alzheimer’s. The deal boosts Sanofi's position in neurodegenerative disease treatment innovation.
BioNTech Invests $1.3B in UK R&D and AI Centers BioNTech Biotech BioNTech announces a $1.3 billion investment in the UK to establish R&D hubs in Cambridge and London, create 400+ jobs, and launch an AI center to accelerate drug discovery and personalized therapies.
Merck KGaA Advances Lupus Drug Enpatoran to Phase 3 Merck Biotech Merck KGaA advances its lupus drug enpatoran into phase 3 after positive phase 2 results in cutaneous lupus, despite setbacks in systemic lupus cohorts. The drug shows strong efficacy and a favorable safety profile.
Accropeutics' AC-201 TYK2/JAK1 Inhibitor Shows Strong Phase 2 Psoriasis Trial Results Biotech Accro Bioscience Accropeutics Accropeutics’ TYK2/JAK1 inhibitor AC-201 achieved positive phase 2 results in treating moderate to severe plaque psoriasis in China, showing strong efficacy and safety, with plans to accelerate clinical development.
France Funds OSE's €1.3M mRNA Therapy Project OSE Immunotherapeutics French biotech OSE Immunotherapeutics secures €1.3M government funding to lead HexARN project, advancing mRNA therapeutics for inflammatory diseases with partners Inside Therapeutics and University of Angers.
FDA Panel Supports Darzalex for Early Myeloma Darzalex Johnson&Johnson Biotech FDA Johnson & Johnson's Darzalex Faspro gains FDA advisory backing as a potential first treatment for high-risk smoldering multiple myeloma, despite concerns over trial design, patient selection, and long-term efficacy.
Moderna Delays Flu/COVID Combo Shot Filing Moderna Moderna has withdrawn its FDA application for the mRNA-1083 flu/COVID-19 combo vaccine after agency discussions, planning to resubmit later in 2025 with Phase III flu vaccine data amid shifting U.S. regulatory requirements.
SK Bioscience Wins Key Patent Battle SK Bioscience Pfizer SK Bioscience wins a key patent dispute against Pfizer in South Korea, enabling global exports of its 13-valent pneumococcal vaccine. The company plans expansion into Southeast Asia and Latin America while advancing next-gen vaccine R&D.